Arrowhead pause raises more questions about lung delivery
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
New Glaxo: it’s all about the late-stage assets
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
Pfizer reveals its PD-1 secret
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
Glaxo’s growth problem
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
Why ipatasertib is not the Akt Astra wants to follow
The repeated failure of Roche’s ipatasertib increases the risk for Astrazeneca’s rival Akt inhibitor capivasertib.
